echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > NMPA accepts new drug application for Tanbey Mitsubishi Tenelia 20mg tablet

    NMPA accepts new drug application for Tanbey Mitsubishi Tenelia 20mg tablet

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, Japanese pharmaceutical company MitsubishiPharmaceutical(http://(http:// announcedthat China's StateDrug(http://Regulatory Authority (NMPA) has accepted a regulatory application for 20mg tablets submitted by its Chinese subsidiary, Tianbian Mitsubishi Pharmaceutical Research and Development (Beijing) Co., Ltdabout TeneliaTenelia is a dipeptide-based peptidease-4 (DPP-4) inhibitor, found by MTPC, the drug is administered once a day to effectively reduce post-meal blood sugar levels and short-range blood sugar levelsTenelia does not need to be adjusted for renal or liver insufficiency and can therefore be used in a wide range of people with type 2 diabetesIn February, MTPC's manufacturing and sales subsidiary in China, Tianjin Tianbian Pharmaceutical Co., Ltd., signed a strategic partnership with Svia Pharmaceuticals Co., Ltdin China to promote Tenelia, a drug(http://by theof Type 2 Diabetes Treatment, in ChinaTenelia, the first DPP-4 inhibitor from Japan, was first launched in Japan in 2012 and has since been gradually launched in countries such as South Korea, where it has been hailed as the "ideal anti-sugar drug" Mitsubishi Pharmaceuticals, through a partnership with Svia, offers new treatments to better control blood sugar in chinese diabetics
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.